Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809190 | 0.86 | CYP3A4 (0.66) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Pheneridine SCHEMBL1922392 | 0.85 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL3566447 | 0.83 | SLC6A3 (0.54) | OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL18458294 | 0.82 | KCNA3 (0.58) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL11565095 | 0.82 | CA12 (0.59) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL11565716 | 0.79 | KCNA3 (0.54) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL11565333 | 0.79 | OPRM1 (0.73) | KCNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL11565335 | 0.79 | KCNA3 (0.52) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL11402199 | 0.79 | KCNA3 (0.54) | KCNA3OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL11564720 | 0.78 | KCNA3 (0.53) | KCNA3OPRM1OPRD1OPRK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |